Research Use Only Legal and Compliance Policy

Purpose of this policy

This policy defines the intended customers and permitted use of Sterling research materials. It supports order screening, product communication and consistent handling of enquiries. It does not replace laws, licences, ethics approvals or the purchasing organisation’s risk assessment.

All products are offered for qualified laboratory research unless a product record expressly establishes another lawful status. Website design, analytical purity or a Certificate of Analysis does not transform a research material into an approved medicine, food, supplement, cosmetic, diagnostic or veterinary product.

Permitted research context

Permitted work can include analytical method development, chemical characterisation, receptor or enzyme assays, binding studies, controlled cell research, formulation research and appropriately authorised preclinical investigation. The organisation must have competent personnel, suitable facilities, safety procedures and any required approvals.

The exact permitted use depends on the material and jurisdiction. A project can be scientific yet still require ethics, animal-research, medicines, controlled-substance, transport, environmental or other authorisation. The purchaser is responsible for identifying and meeting those requirements.

Sterling may ask for the organisation, institutional email, project description, delivery facility, responsible investigator or procurement authority. Information requests should remain proportionate and handled under the privacy policy.

Prohibited uses

Sterling materials must not be used for:

• administration to a human or animal;
• diagnosis, prevention, treatment or claimed cure of disease or injury;
• personal experimentation, injection, ingestion, implantation or topical application;
• athletic performance, recovery, body composition or anti-doping evasion;
• manufacture of an unapproved medicine, supplement, food, cosmetic or veterinary product;
• consumer resale, repackaging or relabelling that obscures research-only status;
• use by a person or facility lacking appropriate competence or approvals;
• unlawful import, export, possession, transport or disposal.

This list is not exhaustive. Sterling can reject any purpose that creates a reasonable compliance, safety, fraud or reputational concern.

No medical or veterinary advice

Product pages and research guides discuss chemical identity, analytical evidence and published research. They do not diagnose a condition, recommend a treatment or provide a dose. Staff must not answer questions about cycles, injection sites, self-administration, clinical reconstitution, combining substances or managing adverse effects.

Anyone facing a medical concern should contact an appropriately qualified healthcare professional or emergency service. Sterling cannot assess symptoms or provide poison-management advice. Laboratories should maintain their own emergency and exposure procedures.

Veterinary administration is equally outside scope. An animal experiment conducted under an approved research protocol is different from treating a pet, livestock or performance animal.

UK medicinal-product classification

The Human Medicines Regulations definition considers both presentation and function. A substance presented as treating or preventing disease can be a medicinal product. A substance used or administered to restore, correct or modify physiological function through pharmacological, immunological or metabolic action can also fall within the definition.

The MHRA guide to what is a medicinal product explains the classification approach. It notes that unauthorised medicinal products cannot lawfully be sold, supplied or advertised as though authorised. Sterling content must avoid therapeutic presentation.

Placing “not for human consumption” beside clinical benefits does not necessarily remove medicinal presentation. The whole context, wording, imagery, instructions, audience and actual supply can matter. Borderline projects require specialist regulatory advice.

Purchaser representations

By submitting an order, the purchaser should confirm that it acts for a legitimate research purpose, is authorised to acquire the materials, has competent personnel and facilities, and will comply with applicable law and institutional controls.

The purchaser should confirm that order and account information is accurate and that the delivery location can receive and store the material. It must not conceal end use, use an intermediary to bypass a refusal or provide misleading organisation details.

These representations do not shift every supplier responsibility to the purchaser. Sterling must still communicate accurately, perform proportionate checks and comply with its own legal duties.

Order screening

Screening can consider account information, email domain, organisation website, order pattern, quantities, delivery address, messages and product combination. Automated signals may support but should not make unfair or unexplained decisions without appropriate review.

Indicators of personal use include requests for dosage, injection supplies for self-use, treatment outcomes, body-weight calculations, athletic cycles or delivery arrangements inconsistent with a laboratory. Staff should stop advice and escalate the order.

Sterling may request clarification, restrict quantity, hold, cancel or refuse an order. Payment authorisation does not prevent that action. Any refund should follow the payment policy.

Age and authority

An age-confirmation interface can discourage minors, but a click alone does not prove identity, competence or institutional authority. Sterling’s intended customers are adults acting for qualified research organisations.

The purchaser must have authority to bind or buy for the named organisation. Students and junior staff should use their institution’s approved procurement route and responsible supervisor rather than opening an unsupported personal account.

Product claims and communications

Sterling must describe analytical results accurately. HPLC purity cannot be presented as clinical effectiveness, sterility or complete safety. Published research should be summarised with its evidence level and limitations.

Testimonials about personal effects are not acceptable evidence and should not be published as verified research reviews. The review system should contain genuine, consented, traceable customer feedback about service or documentation, not fabricated medical outcomes.

Affiliates, advertisers and staff must follow the same boundary. Sterling should not commission others to make claims it would not lawfully make itself.

Training and audit

Staff who handle catalogue copy, sales, support, fulfilment or reviews should receive role-specific research-use training before accessing live systems. Training should cover prohibited claims, personal-use indicators, escalation, accurate analytical language, privacy and preservation of order records.

Sterling should periodically sample published pages, support conversations, refused orders and affiliate material. The review should test whether the stated policy matches actual decisions and whether similar cases receive consistent treatment. Findings need an owner, corrective action and completion date.

A policy breach can require content removal, account restriction, order cancellation, affiliate termination or regulatory advice. Enforcement should be proportionate and documented. A customer should be allowed to correct an innocent administrative error, but deliberate evasion, false end-use information or attempts to obtain self-administration advice justify stronger action.

The operator should maintain a controlled policy version and record the date, approver and reason for change. Staff must use the current version rather than informal sales language.

Reports of diversion or misuse

Anyone who becomes aware of suspected diversion, misleading resale, relabelling or prohibited product claims can report the product, batch, account or page through the technical support desk. Reports should contain observable facts and must not include unlawful access or unnecessary personal data.

Sterling should preserve relevant order and communication records, assess the credibility and urgency of the report, restrict further supply where justified and seek specialist advice when notification may be required. A report is not proof; decisions should be evidence-led and avoid public disclosure during review.

Resale and transfer

Purchasers must not resell into consumer, clinical, sport or veterinary channels. Institutional transfer between authorised sites should preserve label, batch, CoA, storage and chain-of-custody records and comply with contracts and law.

Repackaging can introduce contamination, quantity and identity risk. It must occur only within an appropriate quality system and must not remove supplier or research-only information. Sterling can restrict resale by contract where lawful.

Storage, handling and disposal

Purchasers are responsible for risk assessment, personal protective equipment, engineering controls, storage, spill response and disposal. The storage protocol is an SOP framework, not a complete safety assessment.

Unknown toxicology requires conservative handling. Avoid skin contact, inhalation and environmental release. Dispose under institutional chemical or biological waste procedures, not through domestic drains or rubbish.

Suspected exposure should follow the organisation’s emergency plan and appropriate professional advice. Retain the product label, batch and safety information for responders.

Research ethics and animal work

Animal research requires applicable licences, ethical review, competent facilities and welfare controls. A product order does not demonstrate that those permissions exist. Sterling may ask for institutional confirmation where a proposed use raises concern.

Human-derived cells, tissues or data can also trigger ethics, consent, biosafety and data-protection requirements even when the peptide is not administered to a person. Researchers must assess the whole project.

Reporting concerns

Report suspected diversion, counterfeit communication, incorrect labels, damaged product or inappropriate marketing through the technical support desk. Provide objective evidence and do not publish sensitive personal or security information.

Sterling should document, investigate and escalate credible concerns. It may suspend accounts, preserve records, notify processors, carriers or authorities where legally required, and correct public information.

Policy enforcement and review

Violation can result in order cancellation, account restriction, refusal of future supply and other lawful action. Enforcement should be consistent, evidence-based and proportionate. Customers should have a route to correct factual errors.

This policy is published for Sterling Research Group Ltd and requires review when products, law, guidance, markets or procedures change. The WordPress revision history records editorial changes, while the operator remains responsible for approving material compliance updates.

Purchaser checklist

1. Define a legitimate laboratory purpose and exact material.
2. Confirm legal, ethics, safety and institutional authority.
3. Review specification, batch evidence and storage requirements.
4. Use an approved organisational account and delivery facility.
5. Keep all work outside human, veterinary and consumer application.
6. Preserve traceability through storage, preparation, transfer and disposal.
7. Contact support when the permitted boundary or documentation is unclear.

For broader planning, read the complete research peptides UK guide and the terms of laboratory supply.